The concept of “induced proximity” in cell-cell interactions is an emerging strategy in immunotherapy, where molecules bring immune cells and target cells into close contact, facilitating immune-mediated cell killing. Antibody Recruiting Molecules (ARMs) and Covalent Immune Recruiters (CIRs) represent pioneering classes of bifunctional molecules designed to implement this strategy by promoting proximity between endogenous antibodies (or immune cells) and disease-associated cells. By inducing targeted immune activation through controlled cell-cell interactions, ARMs and CIRs create innovative pathways for treating complex diseases such as cancer and infectious diseases. This essay delves into how these ARMs and CIRs leverage induced proximity, examining their mechanisms, design, applications, and potential challenges.

Antibody Recruiting Molecules (ARMs)

Redirecting endogenous antibodies to tumor cells using synthetic molecules offers a promising method for triggering anti-tumor immune responses. Traditional designs, however, utilize only a limited portion of endogenous antibodies, reducing therapeutic impact. ARMs represent an innovative approach to redirect the immune response towards cancer cells by exploiting endogenous antibodies naturally present in the human bloodstream.

ARMs are bifunctional synthetic molecules designed to bridge the gap between cancer cells and the immune system (Fig. 1).

 

Fig. 1: Antibody Recruiting Molecules (ARMs)

Diagram showing antibody-mediated cellular cytotoxicity and phagocytosis of tumor cells with NK cells and macrophages.

Structure and Mechanism

ARMs typically consist of two key components:

  1. Target-binding moiety: This part binds to antigens present on diseased cells, ensuring that the ARMs selectively target abnormal cells over healthy ones.
  2. Antibody-binding moiety: This component is designed to recognize and bind to endogenous antibodies, most commonly those of the immunoglobulin G (IgG) class. In many cases, ARMs are engineered to bind to the constant Fc region of IgG antibodies, facilitating immune cell recognition and clearance.

The specificity and efficacy of ARMs lie in their dual binding capabilities, allowing them to act as a bridge between antibodies and target cells. By exploiting the naturally abundant IgG antibodies, ARMs can effectively bypass the need for monoclonal antibody production, offering a potentially less costly and more versatile therapeutic option.

The mechanism of action for ARMs involves:

  1. Recognition of cancer cells and antibody recruitment, forming ternary complexes.
  2. Interactions between the complex and immune effector cells.
  3. Destruction of cancer cells through immune-mediated clearance.

This approach allows ARMs to transform healthy human serum into a potent weapon against tumors, potentially overcoming obstacles encountered in clinical trials.

Design and Engineering

The design of ARMs requires careful consideration of both target affinity and antibody recruitment specificity. Structurally, ARMs are often built as small-molecule conjugates, making them significantly smaller than conventional antibodies, which may offer advantages in terms of tissue penetration and pharmacokinetics. Recent advancements in molecular design have led to the development of ARMs with improved binding affinity, stability, and selectivity.

  1. Target specificity: ARMs are engineered to recognize and bind to specific disease-associated antigens, which can vary between cancer types or pathogenic organisms. The choice of target antigen is critical, as it dictates the range of diseases that an ARM can address.
  2. Antibody-binding selectivity: ARMs commonly bind to the Fc portion of IgG antibodies (Fc-binding antibody-recruiting molecules or Fc-ARMs), leveraging the immune response without interfering with the antigen-binding site of the antibody. Selectivity is crucial to prevent unintended immune activation and reduce off-target effects. The key advantage of Fc-ARMs is their ability to exploit endogenous antibodies through constant affinity to the Fc region of antibodies, whose sequence is conserved in contrast to the Fab region. Studies have shown that Fc-ARMs targeting folate receptor-α (FR-α) can redirect clinically used antibody mixtures to FR-α–positive cancer cells, resulting in cancer cell lysis by natural killer cells in vitro. Furthermore, Fc-ARMs have demonstrated the ability to interact with antibodies in vivo, accumulate in tumors, and suppress tumor growth in mouse models.
  3. Linker chemistry: The linker connecting the target-binding and antibody-binding components is a crucial aspect of ARM design, as it influences the stability and flexibility of the molecule. Linker optimization can enhance the pharmacokinetics and bioavailability of ARMs, improving their therapeutic potential.

Covalent Immune Recruiters (CIRs)

Covalent immune recruiters represent an evolution of ARMs, designed to form stable, often irreversible bonds with target cells or immune components. Unlike traditional ARMs, which rely on reversible interactions, covalent immune recruiters utilize covalent chemistry to enhance binding stability, ensuring prolonged engagement with the target cells and antibodies. This stability can lead to more robust immune responses and improved therapeutic outcomes.

The covalent bond formation is usually achieved by incorporating electrophilic groups within the immune recruiter molecule, enabling it to form bonds with nucleophilic amino acid residues on target proteins. This strategy increases the duration of immune engagement and provides more sustained immune cell activation

  • Covalent bond formation: Covalent immune recruiters are designed to form irreversible bonds, which can provide longer-lasting therapeutic effects, especially in conditions where continuous immune activation is desired.
  • Improved targeting and clearance: By creating stronger bonds, covalent immune recruiters may reduce the likelihood of immune escape and increase the clearance of disease-associated cells.
  • Potential for lower dosing: Given their prolonged binding, covalent immune recruiters may allow for reduced dosing frequency, which can improve patient compliance and reduce potential side effects.

Structure and Mechanism

CIRs are composed of three key elements:

  1. Covalent labeling unit
  2. Antibody-binding domain
  3. Target-binding domain

The covalent nature of CIRs provides several potential advantages:

  • Increased stability of the antibody-CIR complex
  • Potentially longer-lasting effects
  • Greater control over the immune response
  • Improved targeting and clearance
  • Potential for lower dosing

Therapeutic Applications of ARMs and Covalent Immune Recruiters

The use of ARMs and covalent immune recruiters holds promise across several therapeutic areas, including oncology, infectious diseases, and autoimmune disorders.

Cancer Therapy

ARMs and covalent immune recruiters are highly attractive in cancer immunotherapy due to their potential to enhance immune recognition of tumor cells while minimizing damage to healthy tissues. ARMs targeting tumor-associated antigens, such as prostate-specific membrane antigen (PSMA) in prostate cancer or HER2 in breast cancer, are currently under investigation. By redirecting endogenous antibodies to tumor cells, these molecules promote antibody-dependent cellular cytotoxicity (ADCC) and other immune responses, facilitating tumor cell elimination.

Infectious Diseases

ARMs have been explored as potential treatments for viral and bacterial infections. By recruiting antibodies to specific viral or bacterial epitopes, ARMs can enhance pathogen clearance and reduce the burden of infection. For example, ARMs targeting the HIV-1 virus have been developed to enhance immune recognition and clearance of infected cells, representing a novel approach to antiviral therapy.

Autoimmune Disorders

In autoimmune diseases, selective ARMs could theoretically be used to direct immune responses away from self-antigens, although this application remains in early stages of research. Alternatively, covalent immune recruiters might be designed to deactivate immune cells targeting self-antigens, offering potential for treating diseases like rheumatoid arthritis or lupus.

Challenges and Future Perspectives

While ARMs and covalent immune recruiters offer a promising therapeutic platform, several challenges remain. Off-target effects, immune overactivation, and the risk of adverse reactions are notable concerns that must be addressed to ensure patient safety. In addition, the covalent nature of immune recruiters, while providing durability, may also pose risks of prolonged immune activation, which could lead to autoimmunity or unwanted tissue damage.

Further research is required to optimize ARM design and linker chemistry, minimize potential off-target effects, and enhance target specificity. The development of covalent immune recruiters also demands careful consideration of pharmacodynamics and long-term safety, as their irreversible nature may complicate dosing regimens and increase the risk of toxicity.

Proximity-Based Modalities

The field of induced proximity extends beyond ARMs and CIRs to include a variety of proximity-based modalities. These include protein degraders, blockers, stabilizers, and inducers of protein post-translational modifications.

Mechanisms and Applications

These modalities can be based on:

  • Monovalent molecules (e.g., molecular glues)
  • Bifunctional molecules (e.g., PROTACs)
  • Trivalent or trifunctional molecules

The outcome of induced proximity depends on the target-effector combination, offering opportunities to choose the best modality for desired therapeutic effects.

Conclusion

Cell-cell induced proximity, as exemplified by ARMs, Fc-ARMs, CIRs, and other proximity-based modalities, represents a promising frontier in immunotherapy. These approaches offer the potential to redirect endogenous immune responses with high specificity, potentially overcoming limitations of traditional therapies. As research in this field progresses, we can anticipate further refinements in design and efficacy, potentially leading to significant advancements in cancer treatment and other therapeutic applications.

In Vitro and Cell-Based Assays for ARM and CIR Drug Discovery and Development

In Vitro Assays

Cell-Based Assays

Further Reading

  1. Antibody recruiting molecules (ARMs): synthetic immunotherapeutics to fight cancer
  2. Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses
  3. Covalent Immune Recruiters: Tools to Gain Chemical Control Over Immune Recognition
  4. Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease
  5. Multivalent antibody-recruiting macromolecules: linking increased binding affinities with enhanced innate immune killing
  6. Covalent Stabilization of Antibody Recruitment Enhances Immune Recognition of Cancer Targets
  7. Electrophilic proximity-inducing synthetic adapters enhance universal T cell function by covalently enforcing immune receptor signaling
  8. Extracellular proximal interaction profiling by cell surface–targeted TurboID reveals LDLR as a partner of liganded EGFR

Learn more about Cell-Based Assay Services